Leo International Precision Health AG (LIPH, ticker: LEOW) has announced plans to acquire nine additional portfolio assets across Asia and Europe, with an expected total transaction volume of EUR 400–500 million. The acquisitions are intended to accelerate the commercialization of the company's AI-driven precision health portfolio, which uses machine learning and natural language processing to analyze genomic data and predict patient outcomes.
The first asset: a Japanese beauty clinic network
The first asset from this second batch is the intended acquisition of all shares in the Japanese company Funnel Ad Inc. (Funnel Group), with a projected purchase price of approximately EUR 48 million. Funnel Group operates roughly 50 beauty clinics across Japan through several subsidiaries, including General Incorporated Association Shokeikai, Medical Corporation Seikeikai, Medical Corporation Mitsuhashi clinic, General Incorporated Association Kiboukai, and Medical Corporation Joshinkai.
The clinic network includes established brands such as dio clinic (medical slimming), e-clinic (cosmetic surgery), FIN CLINIC (male cosmetic surgery), and Tokyo Ueno Clinic (urological surgery). These clinics are currently owned by the Hatashita family. The signing of the agreement is expected within the next two to four weeks, with completion anticipated in the second half of 2026, subject to customary closing conditions and successful implementation of planned financing measures.
Strategic rationale
According to LIPH, the clinic network would provide immediate access to a sizeable and profitable healthcare services platform in a key Asian market. Beyond its financial contribution, the acquisition is expected to create strategic and operational synergies within LIPH's portfolio. The clinics are intended to serve as core commercial infrastructure for rolling out additional products and services across the LIPH platform, including diagnostics, nutraceuticals, and AI-driven applications. The platform is also expected to support cross-portfolio synergies by providing physical access points for existing portfolio companies such as Dr. PAIN.
The broader acquisition plan
The management board intends to acquire eight additional assets operating preventative care clinics, beauty clinics, healthcare platforms, as well as biotechnology and medical products businesses across Asia and Europe. The expected purchase price of EUR 400–500 million for all nine assets includes the Japanese clinic chain. Financing is planned through a combination of bank financing, the issuance of a listed corporate bond, and shareholder loans. The nine targeted assets had achieved a total EBITDA of between EUR 50 million and EUR 60 million, mostly in the 2025 financial year.
About the company
LIPH is a holding company building a global integrated AI-driven healthcare ecosystem, focusing on AI-driven precision health assets across Healthcare Services, MedTech, HealthTech, and Biotech. The company offers investors access to the Asian and global healthcare and life sciences market by reconfiguring assets and integrating technology, data, and operations.
Bottom line
LIPH's planned acquisitions represent a significant expansion of its healthcare portfolio, combining operational clinic networks with AI-driven data capabilities. The EUR 400–500 million deal pipeline, anchored by a EUR 48 million Japanese clinic network, aims to create a platform that integrates physical healthcare services with digital and AI-based products. Investors should watch for the signing of the Funnel Ad Inc. agreement and the completion of financing measures in the coming months.